Management of infection in systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by abnormal autoantibody production and clearance. This immunological background has been suggested to play a role in the susceptibility of SLE patients to infection. Moreover, drugs (most of them immunosuppressive or immunomodulating agents) used in the treatment of moderate and severe lupus give rise to a tendency for infections, including opportunistic ones. Infections may mimic the exacerbations of SLE, leading to confusion over the diagnosis and appropriate treatment. Despite increased awareness of this problem, infections remain a major source of morbidity and mortality in SLE. There are various strategies which can be applied to try and reduce the risk of infection in SLE patients. Options include vaccinations, antibiotic/antiviral prophylaxis and intravenous immunoglobulins.
Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK.
Savino
S
Sciascia
Maria Jose
MJ
Cuadrado
Mohammed Yousuf
MY
Karim
D001323:Autoantibodies / Q000097:blood; D001424:Bacterial Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D012307:Risk Factors; D014611:Vaccination; D014612:Vaccines / Q000008:administration & dosage; D014777:Virus Diseases / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D014612:Vaccines
Bacterial viral fungal flare; Immunoglobulin; Vaccination; Vaccine antibiotic prophylaxis